SCHEMBL20008098

SCHEMBL20008098

CO[C@H](COS(N)(=O)=O)[C@@H](O)[C@@H](O)n1cnc2c(Nc3ccc(Cl)cc3)ncnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 2/20 0.41
▸ CCNB2 O95067 1/20 0.41
▸ CCNB1 P14635 1/20 0.41
▸ CCNB3 Q8WWL7 1/20 0.41
▸ ADORA2B P29275 3/20 0.39
▸ ADORA1 P30542 3/20 0.39
▸ ADORA3 P0DMS8 2/20 0.39
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ ADORA2A P29274 2/20 0.37
▸ CA12 O43570 3/20 0.37
▸ CA1 P00915 3/20 0.37
▸ CA2 P00918 3/20 0.37
▸ CA9 Q16790 3/20 0.37
▸ PRMT5 O14744 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ FLT3 P36888 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23080208 0.82 ADK (0.32) —
SCHEMBL23080242 0.80 CCNB2 (0.48) CDK1CCNB2CCNB1CCNB3ADORA1
SCHEMBL20007970 0.78 DNPH1 (0.38) CDK1CCNB2CCNB1CCNB3
SCHEMBL20008382 0.77 ADORA2A (0.32) CDK1CCNB2CCNB1CCNB3ADORA2B
SCHEMBL23080284 0.77 NAE1 (0.59) CA2
SCHEMBL20008410 0.77 ATG7 (0.36) —
SCHEMBL20008212 0.76 ADORA3 (0.34) ADORA3ABL1
SCHEMBL20008037 0.76 ATG7 (0.40) CDK1CCNB2CCNB1CCNB3CA1
SCHEMBL23080286 0.75 ADORA2A (0.36) CDK1CCNB2CCNB1CCNB3ADORA2B
SCHEMBL20008059 0.75 RET (0.33) CDK1CCNB2CCNB1CCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070798-A1 Inhibitors of E1 activating enzymes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-11 — — US disclosed
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. 2018-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 CDK1 14/4885CCNB2 238/4885CCNB1 95/4885
US-20210070798-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 CDK1 4/4885CCNB2 485/4885CCNB1 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback